In the field of biomanufacturing, recombinant protein expression has become a cornerstone for developing various therapeutics and vaccines. Today, a range of biological expression systems are available, including bacteria, yeasts, fungi, mammalian cells, plants, and insect cells. Among yeast systems, Pichia pastoris has gained significant traction as a reliable, standard platform for recombinant protein production due to its high efficiency in folding, secretion, and scalability. These advantages make P. pastoris an excellent choice for producing biologics, including vaccines and other therapeutic proteins.

The BioMaP-Consortium is particularly interested in understanding current capabilities and expertise in utilizing Pichia pastoris for biologics and vaccine production. If your organization has experience or capabilities in using Pichia-based expression systems, we would appreciate your response to the survey linked below.

Survey responses will be accepted until November 21, 2024.

This is not a Request for Project Proposals (RPP). It is strictly a market survey. Neither unsolicited proposals nor any other kinds of offers will be considered in response to this survey. Companies that respond will not be paid for submitting information or administrative costs incurred in response to this survey.  BioMaP-Consortium intends to utilize the information gathered from this survey for planning and market research purposes only. Please be aware that any information submitted as part of this survey will be shared with the US Government.